AB016. A double-blind, placebo-controlled, phase 2 trial of a novel toll-like receptor 7/8/9 antagonist (IMO-8400) in dermatomyositis

Abstract

Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA; Department of Rheumatology, University of Michigan, Ann Arbor, MI, USA; Department of Clinical Immunology, Medical Faculty, University of Debrecen, Debrecen, Hungary; Department of Neurology, University of California Irvine, Irvine, CA, USA; Idera Pharmaceuticals, Inc., Exton, PA, USA Correspondence to: Kavita Y. Sarin; David F. Fiorentino. Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA. Email: [email protected]; [email protected].